Accueil > Actualité
Actualite financiere : Actualite bourse

Sanofi: fast-track procedure granted for Dupixent

( - Sanofi announced on Monday morning that the FDA has granted Breakthrough Therapy designation (allowing it to benefit from a fast-track procedure) to Dupixent, for the treatment of eosinophilic esophagitis.

"Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE). There are currently no FDA-approved treatments for this chronic type 2 inflammatory disease that damages the esophagus and impacts patients' ability to swallow and eat," Sanofi said.

Copyright (c) 2020 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.